Maloney, A., Ansa, G., Craggs, G., Farnie, G., Fawkes, M., Gross, F., Harman, J., Major, S., Milne, T., Robinson, R., Searle, D. E., Simpson, I., Smith, A., Somervaille, T., Pollard, J. (2025). MLLT1/3 targeted protein degradation as the best-in-class approach for targeting the super elongation complex (SEC) in acute leukemia, including menin inhibitor refractory disease. Blood. https://doi.org/10.1182/blood-2025-320